Panbela Therapeutics (PBLA) Competitors $0.28 +0.02 (+5.66%) As of 04/17/2025 11:28 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock PBLA vs. AYTU, APLM, GTBP, CDT, FRTX, CANF, NKGN, RNAZ, AEZS, and ALZNShould you be buying Panbela Therapeutics stock or one of its competitors? The main competitors of Panbela Therapeutics include Aytu BioPharma (AYTU), Apollomics (APLM), GT Biopharma (GTBP), Conduit Pharmaceuticals (CDT), Fresh Tracks Therapeutics (FRTX), Can-Fite BioPharma (CANF), NKGen Biotech (NKGN), TransCode Therapeutics (RNAZ), Aeterna Zentaris (AEZS), and Alzamend Neuro (ALZN). These companies are all part of the "pharmaceutical products" industry. Panbela Therapeutics vs. Aytu BioPharma Apollomics GT Biopharma Conduit Pharmaceuticals Fresh Tracks Therapeutics Can-Fite BioPharma NKGen Biotech TransCode Therapeutics Aeterna Zentaris Alzamend Neuro Panbela Therapeutics (NASDAQ:PBLA) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk. Does the media favor PBLA or AYTU? In the previous week, Aytu BioPharma had 1 more articles in the media than Panbela Therapeutics. MarketBeat recorded 1 mentions for Aytu BioPharma and 0 mentions for Panbela Therapeutics. Panbela Therapeutics' average media sentiment score of 0.00 equaled Aytu BioPharma'saverage media sentiment score. Company Overall Sentiment Panbela Therapeutics Neutral Aytu BioPharma Neutral Which has better valuation & earnings, PBLA or AYTU? Aytu BioPharma has higher revenue and earnings than Panbela Therapeutics. Aytu BioPharma is trading at a lower price-to-earnings ratio than Panbela Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPanbela TherapeuticsN/AN/A-$25.26M-$71.130.00Aytu BioPharma$77.23M0.08-$15.84M-$1.45-0.70 Is PBLA or AYTU more profitable? Panbela Therapeutics has a net margin of 0.00% compared to Aytu BioPharma's net margin of -7.62%. Panbela Therapeutics' return on equity of 0.00% beat Aytu BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets Panbela TherapeuticsN/A N/A -302.61% Aytu BioPharma -7.62%-19.30%-4.80% Which has more volatility & risk, PBLA or AYTU? Panbela Therapeutics has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, Aytu BioPharma has a beta of 0.07, meaning that its share price is 93% less volatile than the S&P 500. Do insiders & institutionals believe in PBLA or AYTU? 4.4% of Panbela Therapeutics shares are held by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are held by institutional investors. 0.0% of Panbela Therapeutics shares are held by company insiders. Comparatively, 3.6% of Aytu BioPharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community prefer PBLA or AYTU? Aytu BioPharma received 237 more outperform votes than Panbela Therapeutics when rated by MarketBeat users. Likewise, 67.11% of users gave Aytu BioPharma an outperform vote while only 62.07% of users gave Panbela Therapeutics an outperform vote. CompanyUnderperformOutperformPanbela TherapeuticsOutperform Votes1862.07% Underperform Votes1137.93% Aytu BioPharmaOutperform Votes25567.11% Underperform Votes12532.89% Do analysts prefer PBLA or AYTU? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Panbela Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Aytu BioPharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryAytu BioPharma beats Panbela Therapeutics on 9 of the 14 factors compared between the two stocks. Get Panbela Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PBLA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PBLA vs. The Competition Export to ExcelMetricPanbela TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.36M$6.46B$5.31B$7.35BDividend YieldN/A3.20%5.45%4.31%P/E Ratio0.006.9521.9417.82Price / SalesN/A231.01380.9497.68Price / CashN/A65.6738.2634.64Price / Book-0.025.936.453.98Net Income-$25.26M$143.22M$3.22B$247.81M7 Day Performance-12.50%4.28%5.85%3.19%1 Month Performance-22.22%-13.11%-9.55%-7.70%1 Year Performance-33.33%-8.51%11.83%1.49% Panbela Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PBLAPanbela TherapeuticsN/A$0.28+5.7%N/A-33.3%$1.36MN/A0.006Upcoming EarningsGap UpAYTUAytu BioPharma0.8426 of 5 stars$1.00-3.7%N/A-63.6%$6.17M$77.23M-0.69160Positive NewsGap UpAPLMApollomics1.6951 of 5 stars$5.63-5.4%$200.00+3,452.4%-87.4%$6.12M$1.22M0.0045Positive NewsGap DownGTBPGT Biopharma3.451 of 5 stars$2.29+2.7%$11.00+380.3%-37.8%$5.81MN/A-0.338Short Interest ↓Positive NewsGap UpCDTConduit Pharmaceuticals0.5153 of 5 stars$0.87-4.6%N/A-99.8%$5.78MN/A-0.023Gap UpFRTXFresh Tracks TherapeuticsN/A$0.94-0.5%N/A+3.9%$5.59M$10.06M-0.6620CANFCan-Fite BioPharma2.145 of 5 stars$1.30-17.2%$14.00+976.9%-39.1%$5.56M$667,000.00-0.738Analyst ForecastNews CoverageGap UpHigh Trading VolumeNKGNNKGen BiotechN/A$0.12+4.3%N/A-88.5%$5.40M$80,000.00-0.02N/ARNAZTransCode Therapeutics2.2095 of 5 stars$0.41+1.5%$20.00+4,778.0%-99.9%$5.37MN/A0.009Analyst ForecastAnalyst RevisionNews CoverageGap DownAEZSAeterna ZentarisN/A$2.85+1.6%N/A-63.7%$5.11M$2.37M-0.1920Analyst ForecastNews CoverageALZNAlzamend Neuro2.1948 of 5 stars$0.79+2.8%$20.00+2,434.9%-90.1%$5.07MN/A0.004Short Interest ↑Gap Down Related Companies and Tools Related Companies Aytu BioPharma Competitors Apollomics Competitors GT Biopharma Competitors Conduit Pharmaceuticals Competitors Fresh Tracks Therapeutics Competitors Can-Fite BioPharma Competitors NKGen Biotech Competitors TransCode Therapeutics Competitors Aeterna Zentaris Competitors Alzamend Neuro Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PBLA) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Panbela Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Panbela Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PBLA Stock Free PBLA Stock Alerts